Entropy Technologies LP Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Entropy Technologies LP lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 43.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,683 shares of the biotechnology company’s stock after selling 1,297 shares during the period. Entropy Technologies LP’s holdings in United Therapeutics were worth $603,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares during the last quarter. Comerica Bank raised its holdings in shares of United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares during the last quarter. Tri Locum Partners LP purchased a new position in shares of United Therapeutics during the second quarter worth $15,959,000. QRG Capital Management Inc. raised its holdings in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its holdings in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after buying an additional 153,700 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $370.86.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,743.40. The trade was a 96.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,396 shares of company stock valued at $42,175,418 over the last ninety days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 3.5 %

UTHR opened at $386.27 on Friday. The firm has a market capitalization of $17.25 billion, a PE ratio of 16.96, a PEG ratio of 1.17 and a beta of 0.56. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The firm’s 50-day moving average price is $362.57 and its 200 day moving average price is $326.65.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the firm earned $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.